BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Report Library

All Reports
Datamonitor Healthcare Infectious Diseases Disease Analysis: Hepatitis C

March 15, 2021

Therapeutic strategies for chronic hepatitis C have evolved rapidly over recent years. Following the debut of Sovaldi in 2013, direct-acting antiviral (DAA) combination regimens containing at least two modes of action (nucleotide NS5B inhibitors, NS5A inhibitors, and NS3/4A protease inhibitors) have rapidly become the standard of care, replacing older interferon-based regimens. The drastic shift to DAA regimens is due to their significant advances in cure rates (=95%), greatly improved tolerability profiles, and shortened treatment durations (down from 48 weeks to 8–12 weeks for most patients).

This Datamonitor Healthcare report contains a Disease Analysis module.

Indications Covered: Hepatitis C (HCV) (Antiviral)
Back to the top Back to the top